Additivity of nebivolol/valsartan single-pill combinations versus other single-pill combinations for hypertension.

ABSTRACT: The single-pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β₁ -selective antagonist/β₃ -agonist, and valsartan (80 mg), a renin-angiotensin-aldosterone system inhibitor, is the only Food and Drug Administration-approved β-blocker/renin-angiotensin-aldosterone system inhibitor SPC for hypertension. Additive effects of four nebivolol/valsartan SPC doses (5 mg/80 mg, 5/160 mg, 10/160 mg, 10/320 mg nebivolol/valsartan) were compared with five Food and Drug Administration-approved non-β-blocker/renin-angiotensin-aldosterone system inhibitor SPCs (aliskiren/hydrochlorothiazide, aliskiren/amlodipine, valsartan/amlodipine, aliskiren/valsartan, and telmisartan/amlodipine). Additivity is the ratio of placebo-adjusted SPC blood pressure (BP) reduction to the p

SUBMITTER: Ishak J 

PROVIDER: S-EPMC5813198 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature